obsessive-compulsive%20disorder
OBSESSIVE-COMPULSIVE DISORDER
Obsessive-compulsive disorder is characterized by the presence of either obsessions or compulsions, but more commonly by both symptoms that can cause marked impairment or distress.
Obsession is a recurrent, persistent, intrusive, unwanted thought, image or urge that cause distressing emotions (eg anxiety and disgust).
Compulsion is a repetitive behavior or mental act that the person feels driven to perform, in order to lessen the distress caused by the obsession.
Anxiety is the central feature of obsessive-compulsive disorder.
  1. Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ. 2006 Aug;333(7565):424-429. PMID: 16931840
  2. March JS, Frances A, Carpenter D, et al. The Expert Consensus Guideline series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(Suppl 4):001-72
  3. Khouzam HR. Obsessive-Compulsive disorder. What to do if you recognize baffling behavior?. Postgrad Med. 1999 Dec;106(7):133-141. PMID: 10608970
  4. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002 Aug;360(9330):397-405. PMID: 12241794
  5. Stein DJ, Denys D, Gloster AT, et al. Obsessive-compulsive disorder: diagnostic treatment issues. Psychiatr Clin North Am. 2009 Sep;32(3):665-685. PMID: 19716996
  6. MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
  7. Malaysian Psychiatric Association. Articles on psychiatry of public interest. Obsessive-compulsive disorder. http://www.psychiatry-malaysia.org/html/ocd.shtml
  8. World Health Organization. International classification of diseases and related health problems. 10th rev. WHO. http://www.who.int/classifications/apps/icd/icd10online. 2007
  9. National Institute of Mental Health. Obsessive-compulsive disorder. 2001
  10. Ciechanowski P, Katon W. Obsessive-compulsive disorder: epidemiology, clinical manifestations, and diagnosis. UpToDate. http://www.uptodate.com/contents/obsessive-compulsive-disorder-in-adults-epidemiology-pathogenesis-clinical-manifestations-course-and-diagnosis. 07 Feb 2011. Accessed 11 Oct 2011
  11. National Institute for Health and Care Excellence. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. CG 31. NICE. http://www.nice.org.uk/CG031. 2006
  12. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Psychiatryonline. http://psychiatryonline.org/content.aspx?bookID=28§ionID=1678180. 2007.
  13. Ciechanowski P, Katon W. Pharmacotherapy for obsessive-compulsive disorder. UpToDate. http://www.uptodate.com/contents/pharmacotherapy-for-obsessive-compulsive-disorder. 18 Feb 2011. Accessed 11 Oct 2011
  14. Abramowitz J. Psychotherapy for obsessive-compulsive disorder. UpToDate. http://www.uptodate.com. Mar 2019. Accessed 11 Oct 2011.
  15. American Psychiatric Association. Obsessive-compulsive and related disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:237.
  16. Koran LM, Simpson HB. Guideline watch (March 2013): American Psychiatric Association (APA) practice guideline for the treatment of patients with obsessive-compulsive disorder. Psychiatryonline. http://psychiatryonline.org/content.aspx?bookid=28§ionid=40634994.
  17. Ministry of Health Singapore. Clinical practice guidelines anxiety disorders. MOH Singapore. http://www.moh.gov.sg/cpg. 2015 Jan.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.